Today: 20 March 2026
Browse Category

NASDAQ:KALV 23 August 2025 - 6 January 2026

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.

Stock Market Today

  • Centene Launches Community Programs Amid Depressed Stock Price: What Investors Should Know
    March 20, 2026, 6:30 AM EDT. Centene Corp subsidiaries have initiated community-focused programs targeting behavioral health, job training, housing support, and diabetes care, aiming to assist underserved populations across major U.S. markets. These efforts come as Centene shares (NYSE:CNC) remain under pressure, with a recent price of $35.57, down 13.7% in the past month and 40.3% over one year. Investors should monitor these initiatives closely for insights into Centene's regulatory relations and potential impact on medical loss ratios and membership retention. Despite current headwinds, the stock trades nearly 17% below analyst targets and is marked as undervalued by Simply Wall St. Key risks include rising costs without clear reimbursement or measurable health outcomes.
Go toTop